Pulmonary Drugs Market Report 2026
Pulmonary Drugs Market Global Report 2026 Market Report Infographic Image

Published : April 2026

Pages : 175

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Pulmonary Drugs Market Report 2026

Global Outlook – By Drug Class (Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes), By Indication (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications), By Distribution Channel (Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies) – Market Size, Trends, Strategies, and Forecast to 2035

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Purchase This Report Download Sample PDF
Item added to cart!

Pulmonary Drugs Market Overview

• Pulmonary Drugs market size has reached to $56.98 billion in 2025

• Expected to grow to $74.14 billion in 2030 at a compound annual growth rate (CAGR) of 5.4%

• Growth Driver: Rising Prevalence Of Respiratory Diseases Driving Demand For Pulmonary Drugs Due To Increasing Infectious Disease Burden

• Market Trend: Verona Pharma’s Ohtuvayre™ Approval Marks First Novel COPD Therapy in Over Two Decades

North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Pulmonary Drugs Market?

Pulmonary drugs refer to medications that target the respiratory system to improve lung function, reduce inflammation, and manage airway disorders. They are used for treating conditions such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and other respiratory illnesses.

The main drug class of pulmonary drugs is inhaled corticosteroids, long-acting beta-2 agonists, antihistamines, vasodilators, short acting beta-2 agonists, and others. Inhaled corticosteroids are anti-inflammatory medications delivered directly to the lungs via inhalers to manage chronic respiratory conditions like asthma and COPD by reducing airway inflammation and preventing flare-ups. The various indications include asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, pulmonary arterial hypertension, cystic fibrosis, and others and they are distributed through several channels such as retail pharmacies, online pharmacies, and hospital pharmacies.

Pulmonary Drugs Market Global Report 2026 Market Report bar graph

What Is The Pulmonary Drugs Market Size and Share 2026?

The pulmonary drugs market size has grown strongly in recent years. It will grow from $56.98 billion in 2025 to $60.07 billion in 2026 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to increasing asthma prevalence, rising COPD incidence, urban air pollution growth, expansion of inhalation drug delivery, improved diagnosis of respiratory diseases.

What Is The Pulmonary Drugs Market Growth Forecast?

The pulmonary drugs market size is expected to see strong growth in the next few years. It will grow to $74.14 billion in 2030 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to aging population growth, expansion of biologic pulmonary drugs, precision respiratory medicine adoption, increasing smoking-related disorders, improved access to inhaled therapies. Major trends in the forecast period include rising adoption of targeted respiratory therapies, growth of combination inhalation treatments, increasing focus on long-term disease control, expansion of biologic-based pulmonary drugs, shift toward personalized respiratory care.

Customer representative image Book your 30 minutes free consultation with our research experts

Global Pulmonary Drugs Market Segmentation

1) By Drug Class: Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes

2) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications

3) By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies

Subsegments:

1) By Inhaled Corticosteroids: Beclomethasone, Budesonide, Fluticasone, Mometasone, Ciclesonide

2) By Long-Acting Beta-2 Agonists: Salmeterol, Formoterol, Indacaterol, Olodaterol, Vilanterol

3) By Antihistamines: Cetirizine, Loratadine, Fexofenadine, Diphenhydramine, Levocetirizine

4) By Vasodilators: Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin Analogues

5) By Short-Acting Beta-2 Agonists (SABA): Albuterol, Levalbuterol, Terbutaline, Fenoterol, Pirbuterol

6) By Other Drug Classes: Monoclonal Antibodies, Enzymes, Antibiotics, Antileukotrienes

What Is The Driver Of The Pulmonary Drugs Market?

The increasing prevalence of respiratory diseases is expected to propel the growth of the pulmonary drugs market going forward. Respiratory disorders refer to medical conditions that affect the lungs and airways, impairing normal breathing and oxygen exchange. Respiratory disorders are increasing due to the growing prevalence of smoking, leading to lung damage and chronic diseases. Pulmonary drugs play a crucial role in managing respiratory disorders by improving lung function, reducing inflammation, and relieving airway obstruction for better breathing. For instance, in May 2025, according to the Centers for Disease Control and Prevention, a US-based government agency reported that in 2023, the age-adjusted COPD prevalence among adults 18+ was 3.8%, with higher rates in women (4.1%) than men (3.4%). COPD prevalence rose sharply with age, from 0.4% in adults 18–24 to 10.5% in those 75 and older. Therefore, the rising respiratory diseases are driving the growth of the pulmonary drugs industry.

Key Players In The Global Pulmonary Drugs Market

Major companies operating in the pulmonary drugs market are AstraZeneca plc, GlaxoSmithKline plc, Novartis AG, Boehringer Ingelheim International GmbH, Chiesi Farmaceutici S.p.A., Cipla Limited, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bayer AG, United Therapeutics Corporation, Sanofi S.A., F. Hoffmann-La Roche Ltd., Pfizer Inc., Merck Sharp & Dohme Limited, Glenmark Pharmaceuticals Limited, Lupin Pharmaceuticals Inc., Grifols S.A., Mallinckrodt Pharmaceuticals plc, Circassia Pharmaceuticals plc, AbbVie Inc.

Global Pulmonary Drugs Market Trends and Insights

Major companies operating in the pulmonary drugs market are focusing on therapeutic innovation, such as dual PDE3 and PDE4 inhibition via inhaled delivery, to combine bronchodilator and non-steroidal anti-inflammatory effects in a single molecule for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Dual PDE3 and PDE4 inhibition enables simultaneous airway relaxation and reduction of lung inflammation, addressing persistent COPD symptoms more effectively than traditional therapies and simplifying administration without requiring complex inhalation techniques. For instance, in June 2024, Verona Pharma plc, a UK-based biopharmaceutical company, received U.S. FDA approval for Ohtuvayre (ensifentrine), the first inhaled therapy with this dual-mechanism profile in more than 20 years. Delivered via standard jet nebulizer, Ohtuvayre provides bronchodilator and anti-inflammatory benefits in a single dose, showing clinical efficacy both as monotherapy and in combination with other maintenance treatments in the Phase 3 ENHANCE trials, and is expected to be available through specialty pharmacies in the U.S. by the third quarter of 2024.

Need data on a specific region in this market?

What Are Latest Mergers And Acquisitions In The Pulmonary Drugs Market?

In September 2024, Roivant Sciences Ltd., a US-based biotechnology company, acquired medicine for pulmonary hypertension manufactured by Bayer AG for an undisclosed amount. With this acquisition, Roivant aims to expand its respiratory portfolio and advance innovative treatments for pulmonary hypertension, enhancing patient outcomes and addressing unmet medical needs. Bayer AG is a Germany-based company that manufactures pulmonary drugs, including treatments for respiratory conditions such as pulmonary hypertension.

Regional Insights

North America was the largest region in the pulmonary drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Pulmonary Drugs Market?

The pulmonary drugs market consists of the sales of inhalers, nebulizers, bronchodilators, anti-inflammatory agents, and combination therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Pulmonary Drugs Market Report 2026?

The pulmonary drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pulmonary drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abhilash Pyata

Pulmonary Drugs Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2026 $60.07 billion
Revenue Forecast In 2035 $74.14 billion
Growth Rate CAGR of 5.4% from 2026 to 2035
Base Year For Estimation 2025
Actual Estimates/Historical Data 2020-2025
Forecast Period 2026 - 2030 - 2035
Market Representation Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered Drug Class, Indication, Distribution Channel
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled AstraZeneca plc, GlaxoSmithKline plc, Novartis AG, Boehringer Ingelheim International GmbH, Chiesi Farmaceutici S.p.A., Cipla Limited, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bayer AG, United Therapeutics Corporation, Sanofi S.A., F. Hoffmann-La
Customization ScopeRequest for Customization
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Pulmonary Drugs Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Pulmonary Drugs Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Pulmonary Drugs Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Pulmonary Drugs Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Artificial Intelligence & Autonomous Intelligence

4.1.3 Digitalization, Cloud, Big Data & Cybersecurity

4.1.4 Industry 4.0 & Intelligent Manufacturing

4.1.5 Sustainability, Climate Tech & Circular Economy

4.2. Major Trends

4.2.1 Rising Adoption Of Targeted Respiratory Therapies

4.2.2 Growth Of Combination Inhalation Treatments

4.2.3 Increasing Focus On Long-Term Disease Control

4.2.4 Expansion Of Biologic-Based Pulmonary Drugs

4.2.5 Shift Toward Personalized Respiratory Care

5. Pulmonary Drugs Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Pulmonology Clinics

5.3 Specialty Respiratory Centers

5.4 Homecare Providers

5.5 Ambulatory Care Centers

6. Pulmonary Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Pulmonary Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Pulmonary Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Pulmonary Drugs Market Size, Comparisons And Growth Rate Analysis

7.3. Global Pulmonary Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Pulmonary Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Pulmonary Drugs Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Pulmonary Drugs Market Segmentation

9.1. Global Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes

9.2. Global Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications

9.3. Global Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies

9.4. Global Pulmonary Drugs Market, Sub-Segmentation Of Inhaled Corticosteroids, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Beclomethasone, Budesonide, Fluticasone, Mometasone, Ciclesonide

9.5. Global Pulmonary Drugs Market, Sub-Segmentation Of Long-Acting Beta-2 Agonists, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Salmeterol, Formoterol, Indacaterol, Olodaterol, Vilanterol

9.6. Global Pulmonary Drugs Market, Sub-Segmentation Of Antihistamines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Cetirizine, Loratadine, Fexofenadine, Diphenhydramine, Levocetirizine

9.7. Global Pulmonary Drugs Market, Sub-Segmentation Of Vasodilators, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin Analogues

9.8. Global Pulmonary Drugs Market, Sub-Segmentation Of Short-Acting Beta-2 Agonists, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Albuterol, Levalbuterol, Terbutaline, Fenoterol, Pirbuterol

9.9. Global Pulmonary Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Monoclonal Antibodies, Enzymes, Antibiotics, Antileukotrienes

10. Pulmonary Drugs Market Regional And Country Analysis

10.1. Global Pulmonary Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Pulmonary Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Pulmonary Drugs Market

11.1. Asia-Pacific Pulmonary Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Pulmonary Drugs Market

12.1. China Pulmonary Drugs Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Pulmonary Drugs Market

13.1. India Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Pulmonary Drugs Market

14.1. Japan Pulmonary Drugs Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

14.2. Japan Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Pulmonary Drugs Market

15.1. Australia Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Pulmonary Drugs Market

16.1. Indonesia Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Pulmonary Drugs Market

17.1. South Korea Pulmonary Drugs Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

17.2. South Korea Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Pulmonary Drugs Market

18.1. Taiwan Pulmonary Drugs Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

18.2. Taiwan Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Pulmonary Drugs Market

19.1. South East Asia Pulmonary Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

19.2. South East Asia Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Pulmonary Drugs Market

20.1. Western Europe Pulmonary Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

20.2. Western Europe Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Pulmonary Drugs Market

21.1. UK Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Pulmonary Drugs Market

22.1. Germany Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Pulmonary Drugs Market

23.1. France Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Pulmonary Drugs Market

24.1. Italy Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Pulmonary Drugs Market

25.1. Spain Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Pulmonary Drugs Market

26.1. Eastern Europe Pulmonary Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

26.2. Eastern Europe Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Pulmonary Drugs Market

27.1. Russia Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Pulmonary Drugs Market

28.1. North America Pulmonary Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

28.2. North America Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Pulmonary Drugs Market

29.1. USA Pulmonary Drugs Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

29.2. USA Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Pulmonary Drugs Market

30.1. Canada Pulmonary Drugs Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

30.2. Canada Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Pulmonary Drugs Market

31.1. South America Pulmonary Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

31.2. South America Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Pulmonary Drugs Market

32.1. Brazil Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Pulmonary Drugs Market

33.1. Middle East Pulmonary Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

33.2. Middle East Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Pulmonary Drugs Market

34.1. Africa Pulmonary Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

34.2. Africa Pulmonary Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Pulmonary Drugs Market Regulatory and Investment Landscape

36. Pulmonary Drugs Market Competitive Landscape And Company Profiles

36.1. Pulmonary Drugs Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. Pulmonary Drugs Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. Pulmonary Drugs Market Company Profiles

36.3.1. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

36.3.2. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

36.3.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

36.3.4. Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis

36.3.5. Chiesi Farmaceutici S.p.A. Overview, Products and Services, Strategy and Financial Analysis

37. Pulmonary Drugs Market Other Major And Innovative Companies

Cipla Limited, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bayer AG, United Therapeutics Corporation, Sanofi S.A., F. Hoffmann-La Roche Ltd., Pfizer Inc., Merck Sharp & Dohme Limited, Glenmark Pharmaceuticals Limited, Lupin Pharmaceuticals Inc., Grifols S.A., Mallinckrodt Pharmaceuticals plc, Circassia Pharmaceuticals plc, AbbVie Inc.

38. Global Pulmonary Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Pulmonary Drugs Market

40. Pulmonary Drugs Market High Potential Countries, Segments and Strategies

40.1 Pulmonary Drugs Market In 2030 - Countries Offering Most New Opportunities

40.2 Pulmonary Drugs Market In 2030 - Segments Offering Most New Opportunities

40.3 Pulmonary Drugs Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Pulmonary Drugs Market, Overview Of Key Products - Product Examples
  • Table 2: Global Pulmonary Drugs Market Attractiveness, Factor-Wise Evaluation
  • Table 3: Global Pulmonary Drugs Market, Supply Chain Analysis
  • Table 4: Global Pulmonary Drugs Market, Major Raw Material Providers
  • Table 5: Global Pulmonary Drugs Market, Major Resource Providers
  • Table 6: Global Pulmonary Drugs Market, Major Manufacturers (Suppliers)
  • Table 7: Global Pulmonary Drugs Market, Major Distributors And Channel Partners
  • Table 8: Global Pulmonary Drugs Market, Key Technologies & Future Trends
  • Table 9: Global Pulmonary Drugs Market, Major Trends
  • Table 10: Global Pulmonary Drugs Market, Major End Users
  • Table 11: Global Pulmonary Drugs Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Table 12: Global Pulmonary Drugs Historic Market Growth, 2020-2025, $ Billion
  • Table 13: Global Pulmonary Drugs Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Table 14: Global Pulmonary Drugs Market - TAM, US$ Billion, 2025
  • Table 15: Global Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 16: Global Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 17: Global Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 18: Global Pulmonary Drugs Market, Sub-Segmentation Of Inhaled Corticosteroids, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 19: Global Pulmonary Drugs Market, Sub-Segmentation Of Long-Acting Beta-2 Agonists, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 20: Global Pulmonary Drugs Market, Sub-Segmentation Of Antihistamines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 21: Global Pulmonary Drugs Market, Sub-Segmentation Of Vasodilators, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 22: Global Pulmonary Drugs Market, Sub-Segmentation Of Short-Acting Beta-2 Agonists, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 23: Global Pulmonary Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 24: Global Pulmonary Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 25: Global Pulmonary Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 26: Asia-Pacific, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 27: Asia-Pacific, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 28: Asia-Pacific, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 29: China, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 30: China, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 31: China, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 32: India, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 33: India, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 34: India, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 35: Japan, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 36: Japan, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 37: Japan, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 38: Australia, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 39: Australia, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 40: Australia, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 41: Indonesia, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 42: Indonesia, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 43: Indonesia, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 44: South Korea, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 45: South Korea, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 46: South Korea, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 47: Taiwan, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 48: Taiwan, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 49: Taiwan, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 50: South East Asia, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 51: South East Asia, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 52: South East Asia, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 53: Western Europe, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 54: Western Europe, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 55: Western Europe, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 56: UK, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 57: UK, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 58: UK, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 59: Germany, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 60: Germany, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 61: Germany, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 62: France, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 63: France, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 64: France, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 65: Italy, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 66: Italy, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 67: Italy, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 68: Spain, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 69: Spain, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 70: Spain, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 71: Eastern Europe, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 72: Eastern Europe, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 73: Eastern Europe, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 74: Russia, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 75: Russia, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 76: Russia, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 77: North America, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 78: North America, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 79: North America, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 80: USA, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 81: USA, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 82: USA, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 83: Canada, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 84: Canada, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 85: Canada, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 86: South America, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 87: South America, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 88: South America, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 89: Brazil, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 90: Brazil, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 91: Brazil, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 92: Middle East, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 93: Middle East, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 94: Middle East, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 95: Africa, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 96: Africa, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 97: Africa, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 98: Global Pulmonary Drugs Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Table 99: Global Pulmonary Drugs Market - Company Scoring Matrix
  • Table 100: AstraZeneca plc Financial Performance
  • Table 101: GlaxoSmithKline plc Financial Performance
  • Table 102: Novartis AG Financial Performance
  • Table 103: Boehringer Ingelheim International GmbH Financial Performance
  • Table 104: Chiesi Farmaceutici S.p.A. Financial Performance
  • Table 105: Global Pulmonary Drugs Market, Competitive Benchmarking (In USD Billions)
  • Table 106: Global Pulmonary Drugs Market, Competitive Dashboard
  • Table 107: Global Pulmonary Drugs Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Table 108: Global, Pulmonary Drugs Market Size Gain ($ Billion), Segmentation By Drug Class, 2025 – 2030
  • Table 109: Global, Pulmonary Drugs Market Size Gain ($ Billion), Segmentation By Indication, 2025 – 2030
  • Table 110: Global, Pulmonary Drugs Market Size Gain ($ Billion), Segmentation By Distribution Channel, 2025 – 2030

List Of Figures

    Figure 1: Global Pulmonary Drugs Market, Overview Of Key Products - Product Examples
  • Figure 2: Global Pulmonary Drugs Market Attractiveness, Factor-Wise Evaluation
  • Figure 3: Global Pulmonary Drugs Market, Supply Chain Analysis
  • Figure 4: Global Pulmonary Drugs Market, Major Raw Material Providers
  • Figure 5: Global Pulmonary Drugs Market, Major Resource Providers
  • Figure 6: Global Pulmonary Drugs Market, Major Manufacturers (Suppliers)
  • Figure 7: Global Pulmonary Drugs Market, Major Distributors And Channel Partners
  • Figure 8: Global Pulmonary Drugs Market, Key Technologies & Future Trends
  • Figure 9: Global Pulmonary Drugs Market, Major Trends
  • Figure 10: Global Pulmonary Drugs Market, Major End Users
  • Figure 11: Global Pulmonary Drugs Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Figure 12: Global Pulmonary Drugs Historic Market Growth, 2020-2025, $ Billion
  • Figure 13: Global Pulmonary Drugs Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Figure 14: Global Pulmonary Drugs Market - TAM, US$ Billion, 2025
  • Figure 15: Global Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 16: Global Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 17: Global Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 18: Global Pulmonary Drugs Market, Sub-Segmentation Of Inhaled Corticosteroids, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 19: Global Pulmonary Drugs Market, Sub-Segmentation Of Long-Acting Beta-2 Agonists, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 20: Global Pulmonary Drugs Market, Sub-Segmentation Of Antihistamines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 21: Global Pulmonary Drugs Market, Sub-Segmentation Of Vasodilators, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 22: Global Pulmonary Drugs Market, Sub-Segmentation Of Short-Acting Beta-2 Agonists, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 23: Global Pulmonary Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 24: Global Pulmonary Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 25: Global Pulmonary Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 26: Asia-Pacific, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 27: Asia-Pacific, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 28: Asia-Pacific, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 29: China, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 30: China, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 31: China, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 32: India, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 33: India, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 34: India, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 35: Japan, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 36: Japan, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 37: Japan, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 38: Australia, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 39: Australia, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 40: Australia, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 41: Indonesia, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 42: Indonesia, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 43: Indonesia, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 44: South Korea, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 45: South Korea, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 46: South Korea, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 47: Taiwan, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 48: Taiwan, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 49: Taiwan, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 50: South East Asia, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 51: South East Asia, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 52: South East Asia, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 53: Western Europe, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 54: Western Europe, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 55: Western Europe, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 56: UK, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 57: UK, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 58: UK, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 59: Germany, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 60: Germany, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 61: Germany, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 62: France, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 63: France, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 64: France, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 65: Italy, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 66: Italy, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 67: Italy, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 68: Spain, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 69: Spain, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 70: Spain, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 71: Eastern Europe, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 72: Eastern Europe, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 73: Eastern Europe, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 74: Russia, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 75: Russia, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 76: Russia, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 77: North America, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 78: North America, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 79: North America, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 80: USA, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 81: USA, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 82: USA, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 83: Canada, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 84: Canada, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 85: Canada, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 86: South America, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 87: South America, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 88: South America, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 89: Brazil, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 90: Brazil, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 91: Brazil, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 92: Middle East, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 93: Middle East, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 94: Middle East, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 95: Africa, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 96: Africa, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 97: Africa, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 98: Global Pulmonary Drugs Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Figure 99: Global Pulmonary Drugs Market - Company Scoring Matrix
  • Figure 100: AstraZeneca plc Financial Performance
  • Figure 101: GlaxoSmithKline plc Financial Performance
  • Figure 102: Novartis AG Financial Performance
  • Figure 103: Boehringer Ingelheim International GmbH Financial Performance
  • Figure 104: Chiesi Farmaceutici S.p.A. Financial Performance
  • Figure 105: Global Pulmonary Drugs Market, Competitive Benchmarking (In USD Billions)
  • Figure 106: Global Pulmonary Drugs Market, Competitive Dashboard
  • Figure 107: Global Pulmonary Drugs Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Figure 108: Global, Pulmonary Drugs Market Size Gain ($ Billion), Segmentation By Drug Class, 2025 – 2030
  • Figure 109: Global, Pulmonary Drugs Market Size Gain ($ Billion), Segmentation By Indication, 2025 – 2030
  • Figure 110: Global, Pulmonary Drugs Market Size Gain ($ Billion), Segmentation By Distribution Channel, 2025 – 2030

Frequently Asked Questions

The Pulmonary Drugs market was valued at $56.98 billion in 2025, increased to $60.07 billion in 2026, and is projected to reach $74.14 billion by 2030.

The global Pulmonary Drugs market is expected to grow at a CAGR of 5.4% from 2026 to 2035 to reach $74.14 billion by 2035.

Some Key Players in the Pulmonary Drugs market Include, AstraZeneca plc, GlaxoSmithKline plc, Novartis AG, Boehringer Ingelheim International GmbH, Chiesi Farmaceutici S.p.A., Cipla Limited, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bayer AG, United Therapeutics Corporation, Sanofi S.A., F. Hoffmann-La Roche Ltd., Pfizer Inc., Merck Sharp & Dohme Limited, Glenmark Pharmaceuticals Limited, Lupin Pharmaceuticals Inc., Grifols S.A., Mallinckrodt Pharmaceuticals plc, Circassia Pharmaceuticals plc, AbbVie Inc. .

Major trend in this market includes: Verona Pharma’s Ohtuvayre™ Approval Marks First Novel COPD Therapy in Over Two Decades . For further insights on this market. request a sample here

North America was the largest region in the pulmonary drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customer representative image Book your 30 minutes free consultation with our research experts